Novo Nordisk, WeightWatchers
WeightWatchers adds compounded version of Novo's obesity drug to weight-loss program
WeightWatchers said on Tuesday it would offer compounded form of Novo Nordisk's popular obesity drug Wegovy as part of its weight-management programs, sending its shares up 13% in early trading. Soaring demand for weight-loss drugs such as Wegovy and Eli Lilly's Zepbound,
WeightWatchers to offer compounded weight-loss drugs
WeightWatchers will begin selling compounded alternatives to certain weight-loss drugs that are experiencing shortages. Why it matters: Federal law allows companies to sell compounded versions of drugs that are on the FDA's shortages list — which has led to a surge of copycats to the newly popular class of GLP-1 injections.
Novo Nordisk's weight loss drug Wegovy available in France from Tuesday
Novo Nordisk's weight loss drug Wegovy will be available in France from Tuesday. The drug will require a prescription and will not be covered by social security. The main molecule in the medication is also found in the diabetes drug Ozempic which many celebrities have admitted to using to lose weight.
WeightWatchers to offer compounded version of Novo Nordisk's weight-loss drug
WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of its weight-management programs, sending its shares nearly 47% higher to an over two-month closing high.
Novo Nordisk settles US patent fight with Viatris over Ozempic
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
FiercePharma1d
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...
Mass. to play a key role as Novo Nordisk grows beyond Ozempic
Novo Nordisk says Massachusetts plays a key role in its bid to expand beyond its historic focus as a diabetes and obesity ...
Novo Nordisk's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 50% bearish. Among these notable ...
Novo faces ‘Nokia risk’ as it fights Lilly’s homecourt advantage
The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...
Detroit News8d
Novo’s tough month key in ending health stocks’ winning streak
European health-care stocks are set to snap their longest winning streak since March 2010, dragged down by concerns over ...
Becker's Hospital Review1d
Novo Nordisk to invest $158M in insulin plant
Novo Nordisk plans to invest approximately $158 million into revamping its Montes Claros manufacturing facility in Minas Gerais, Brazil, Bloomberg reported Oct. 5.
Novo Nordisk to Invest $158 Million in Brazilian Insulin Plant
Novo Nordisk is investing $158 million to revamp a plant in Brazil responsible for a quarter of the Danish company’s global ...
Mercury vs Novo Business Checking (2024): Which Is Best?
Compare Mercury and Novo Business Checking accounts to determine the best fit for your business. Explore pricing, features, ...
Novo Nordisk has mitigation plans to minimize disruption from port strikes
Danish drugmaker Novo Nordisk said on Tuesday it has mitigation plans in place to minimize or prevent any disruption to its ...